For teens with inflammatory acne, the studied topical hormonal option is clascoterone 1% cream (Winlevi). It blocks DHT-driven oil and inflammation locally, and trials studied boys and girls 12–17 while excluding children under 12 and severe nodular cases. According to the U.S.
National Library of Medicine DailyMed label, clascoterone 1% cream received FDA approval Aug. 26, 2020 for acne vulgaris in patients 12 years and older the DailyMed drug label. A December 2025 narrative review in Dove Medical Press summarizes its efficacy in patients 12 and older with inflammatory lesions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What makes clascoterone hormonal?
- Which teens were studied?
- Who was not included?
- How should families use these limits?
What makes clascoterone hormonal?
Clascoterone is a first-in-class topical androgen-receptor inhibitor. It acts where applied to reduce DHT-driven sebum and inflammation. That local action differs from pills that work throughout the body.
Systemic hormonal options for acne include combined oral contraceptives and spironolactone. Guideline Central's summary of 2024 AAD guidance describes those systemic options as female-only. That leaves topical clascoterone as the studied hormonal option for teen males.
Which teens were studied?
As reported in JAMA Dermatology, two identical Phase 3 trials enrolled 1,440 patients aged 9 and older with moderate-to-severe facial acne the JAMA Dermatology trial report. Entry required 30–75 inflammatory lesions, 30–100 noninflammatory lesions, and an IGA score of 3–4. Treatment was twice daily for 12 weeks. FDA efficacy was based on patients 12 and older.
The Dove Medical Press review reports pooled results in 1,421 patients 12 and older, including adolescents 12–17 of both sexes. Success reached 19.9% with clascoterone versus 7.7% with vehicle, with significant inflammatory-lesion reduction. Post hoc analyses reported similar efficacy and tolerability across age and sex. The Journal of Drugs in Dermatology found comparable results in adolescent 12–17 versus adult subgroups and in male versus female subgroups.
Who was not included?
Children under 12 were not included in the indication. The maker states on the Winlevi official site that younger children, pregnant patients, and breastfeeding patients fall outside the studied use. Pregnant or breastfeeding patients were excluded from trials.
Teens with the most severe inflammatory disease were also left out. The Journal of Drugs in Dermatology trial description excluded more than two facial nodules, nodulocystic acne, and other interfering skin disease. Teens with those nodular patterns were therefore not represented.
How should families use these limits?
Check trial fit before asking about a prescription. The studied group had moderate-to-severe facial acne with both inflammatory and noninflammatory lesions. The non-studied group includes preteens, pregnancy or breastfeeding, and severe nodular disease. Safety monitoring matters during use.
In an HPA-axis study under maximal twice-daily use, 2 of 22 adolescents showed laboratory suppression. The label warns to reduce or stop use if suppression develops. Guideline Central's AAD summary conditionally recommends clascoterone for its high-certainty benefit while noting cost and access concerns. Bring a medication list and ask the clinic about coverage and refills.
- Age 12 or older with facial inflammatory acne
- Moderate-to-severe grade, not mainly nodules or cysts
- No other active skin disease that would interfere
- Not pregnant or breastfeeding
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: How Teens With Inflammatory Acne Can Avoid Overreading the Headline
- Limited Topical Spironolactone Evidence in the 2026 Review: How Teens With Inflammatory Acne Can Avoid Overreading the Headline
- Adult Female Acne Antiandrogen Treatments in a 2026 Review: How Teens With Inflammatory Acne Can Avoid Overreading the Headline